VBLT - Aspire capital fund to purchase up to $20M of ordinary shares of VBL therapeutics

Aspire Capital Fund has entered into an agreement to purchase up to $20M of ordinary share of VBL Therapeutics (VBLT)Proceeds from any sales of ordinary shares will be used for working capital and for general corporate purposes. “This Purchase Agreement provides VBL the opportunity to access capital at the Company's discretion, in a reasonable and efficient manner, to support our ongoing OVAL phase 3 study of VB-111 in patients with platinum-resistant ovarian cancer." said Dror Harats, M.D., Chief Executive Officer Source: Press Release

For further details see:

Aspire capital fund to purchase up to $20M of ordinary shares of VBL therapeutics